Abstract
Some G-protein-coupled receptors display ‘constitutive activity’, that is, spontaneous activity in the absence of agonist1,2,3,4. This means that a proportion of the receptor population spontaneously undergoes an allosteric transition, leading to a conformation that can bind G proteins3. The process has been shown to occur with recombinant receptors expressed at high density, and/or mutated, but also non-mutated recombinant receptors expressed at physiological concentrations5,6,7. Transgenic mice that express a constitutively active mutant of the β 2-adrenergic receptor display cardiac anomalies8; and spontaneous receptor mutations leading to constitutive activity are at the origin of some human diseases9,10. Nevertheless, this process has not previously been found to occur in animals expressing normal levels of receptor3,4. Here we show that two isoforms of the recombinant rat H3 receptor11,12 display high constitutive activity. Using drugs that abrogate this activity (‘inverse agonists’) and a drug that opposes both agonists and inverse agonists (‘neutral antagonist’), we show that constitutive activity of native H3 receptors is present in rodent brain and that it controls histaminergic neuron activity in vivo . Inverse agonists may therefore find therapeutic applications, even in the case of diseases involving non-mutated receptors expressed at normal levels.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Costa, T., Ogino, Y., Munson, P. J., Onaran, H. O. & Rodbard, D. Drug efficacy at guanine nucleotides-binding regulatory protein-linked receptors: thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand. Mol. Pharmacol. 41, 549–560 ( 1992) .
Schütz, W. & Freissmuth, M. Reverse intrinsic activity of antagonists on G protein-coupled receptors. Trends Pharmacol. Sci. 13, 376–380 (1992).
Lefkowitz, R. J., Cotecchia, S., Samama, P. & Costa, T. Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol. Sci. 14, 303 –307 (1993).
Milligan, G., Bond, R. A. & Lee, M. Inverse agonism: pharmacological curiosity or potential therapeutic strategy? Trends Pharmacol. Sci. 16, 10–13 (1995).
Claeysen, S., Sebben, M., Becamel, C., Bockaert, J. & Dumuis, A. Novel brain-specific 5-HT4 receptor splice variants show marked constitutive activity: role of the C-terminal intracellular domain. Mol. Pharmacol. 55, 910– 920 (1999).
Smit, M. et al. Inverse agonism of histamine H2 antagonists accounts for upregulation of spontaneously active histamine H2 receptors. Proc. Natl Acad. Sci. USA 93, 6802– 6807 (1996).
Berg, K. A., Stout, B. D., Cropper, J. D., Maayani, S. & Clarke, W. P. Novel actions of inverse agonists on 5-HT2C receptor systems. Mol. Pharmacol. 55, 863–872 (1999).
Bond, R. A. et al. Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the β2-adrenoceptor. Nature 374, 272–276 ( 1995).
Parma, J. et al. Somatic mutations in the thyrotropin gene cause hyperfunctioning thyroid adenoma. Nature 365, 649– 651 (1993).
Spiegel, A. M. Defects in G protein-coupled signal transduction in human disease. Annu. Rev. Physiol. 58, 143–170 (1996) .
Arrang, J.-M., Garbarg, M. & Schwartz, J.-C. Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 302, 832–837 ( 1983).
Arrang, J.-M. et al. Highly potent and selective ligands for histamine H3 -receptors. Nature 327, 117– 123 (1987).
Lovenberg, T. W. et al. Cloning and functional expression of the human histamine H 3 receptor. Mol. Pharmacol. 55, 1101 –1107 (1999).
Tardivel-Lacombe, J. et al. Cloning and cerebral expression of the guinea pig histamine H3 receptor: evidence for two isoforms. NeuroReport 11, 755–759 ( 2000).
Giros, B. et al. Alternative splicing directs the expression of two D2 dopamine receptor isoforms. Nature 342, 923–926 (1989).
Monsma, F. J., McVittie, L. D., Gerfen, C. R., Mahan, L. C. & Sibley, D. Multiple D2 dopamine receptors produced by alternative splicing. Nature 342, 926–929 (1989).
West, R. E. et al. Identification of two H3-histamine receptor subtypes. Mol. Pharmacol. 38, 610– 613 (1990).
Hill, S. J. et al. International Union of Pharmacology. XIII. Classification of histamine receptors. Pharmacol. Rev. 49, 253–278 (1997).
Harper, E. A., Shankley, N. P. & Black, J. W. Evidence that histamine homologues discriminate between H3-receptors in guinea-pig cerebral cortex and ileum longitudinal muscle myenteric plexus. Brit. J. Pharmacol. 128, 751–759 (1999).
Samama, P., Cotecchia, S., Costa, T. & Lefkowitz, R. J. A mutation-induced activated state of the β2-adrenergic receptor. Extending the ternary complex model. J. Biol. Chem. 268, 4625–4636 (1993).
Kjelsberg, M. A., Cotecchia, S., Ostrowski, J., Caron, M. G. & Lefkowitz, R. J. Constitutive activation of the α1B-adrenergic receptor by all aminoacid substitutions at a single site. J. Biol. Chem. 267, 1430 –1433 (1992).
Ligneau, X. et al. [125I]Iodoproxyfan, a new antagonist to label and visualize cerebral histamine H3 receptors. J. Pharmacol. Exp. Ther. 271, 452–459 (1994).
Clark, E. A. & Hill, S. J. Differential effect of sodium ions and guanine nucleotides on the binding of thioperamide and clobenpropit to histamine H3-receptors in rat cerebral cortical membranes. Brit. J. Pharmacol. 114, 357–362 (1995).
Garbarg, M. et al. S-[2-(4-imidazolyl)ethyl]isothiourea, a highly specific and potent histamine H3 receptor agonist. J. Pharmacol. Exp. Ther. 263, 304–310 (1992).
Ligneau, X. et al. Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist. J. Pharmacol. Exp. Ther. 287, 658–666 ( 1998) .
Arrang, J.-M., Garbarg, M. & Schwartz, J. C. Autoinhibition of histamine release in brain by presynaptic H3-receptors. Neuroscience 15, 553–562 (1985).
Clark, E. A. & Hill, S. J. Sensitivity of histamine H 3 receptor agonist-stimulated [35S]GTPγ[S] binding to pertussis toxin. Eur. J. Pharmacol. 296, 223–225 (1996).
Garbarg, M., Trung Tuong, M. D., Gros, C. & Schwartz, J.-C. Effects of histaminergic ligands on various biochemical indices of histaminergic neuron activity in rat brain. Eur. J. Pharmacol. 164 , 1–11 (1989).
Sasse, A. et al. Novel partial agonists for the histamine H3 receptor with high in vitro and in vivo activity. J. Med. Chem. 42, 4269–4274 (1999).
Yates, S. L. et al. Effects of selected histamine H3 receptor antagonists on tele-methylhistamine levels in rat cerebral cortex. Biochem. Pharmacol. 57, 1059–1066 (1999).
Acknowledgements
We thank D. Dumoulin for technical assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Morisset, S., Rouleau, A., Ligneau, X. et al. High constitutive activity of native H3 receptors regulates histamine neurons in brain. Nature 408, 860–864 (2000). https://doi.org/10.1038/35048583
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/35048583
This article is cited by
-
Migraine signaling pathways: amino acid metabolites that regulate migraine and predispose migraineurs to headache
Molecular and Cellular Biochemistry (2022)
-
Natural products for infectious microbes and diseases: an overview of sources, compounds, and chemical diversities
Science China Life Sciences (2022)
-
Inhibition of histamine receptor H3 suppresses the growth and metastasis of human non-small cell lung cancer cells via inhibiting PI3K/Akt/mTOR and MEK/ERK signaling pathways and blocking EMT
Acta Pharmacologica Sinica (2021)
-
Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation
Psychopharmacology (2021)
-
Molecular dynamics of the histamine H3 membrane receptor reveals different mechanisms of GPCR signal transduction
Scientific Reports (2020)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.